Boston Scientific’s Device To Relieve Severe Asthma: A Major Opportunity – Seeking Alpha

Boston Scientific's Device To Relieve Severe Asthma: A Major Opportunity
Seeking Alpha
Earlier in 2012 Boston Scientific's incoming CEO Michael Mahoney said about the Alair asthma treatment that it will be marketed in 20 countries and 200 sites by the end of the 2012. Mahoney predicted that the worldwide market for bronchial thermoplasty

View full post on asthma – Google News

Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript – Seeking Alpha

Palatin Technologies CEO Discusses F3Q2011 Results – Earnings Call Transcript
Seeking Alpha
On the next program, I would like to talk about is PL-3994, our natriuretic peptide receptor agonist in development as a treatment for acute exacerbations of asthma. Acute exacerbations of asthma, also called acute severe asthma, is an ongoing asthma
Palatin Technologies, Inc. Reports Third Quarter Fiscal Year 2011 ResultsPR Newswire (press release)

all 20 news articles »

View full post on asthma – Google News